Universität zu Köln

Journal Article

Tober-Lau, Pinkus ORCID: 0000-0002-9148-3663, Gruell, Henning, Vanshylla, Kanika ORCID: 0000-0003-4552-9170, Koch, Willi M., Hillus, David, Schommers, Philipp, Suarez, Isabelle, Suttorp, Norbert ORCID: 0000-0002-3958-1151, Sander, Leif Erik, Klein, Florian ORCID: 0000-0003-1376-1792 and Kurth, Florian ORCID: 0000-0002-3807-473X (2022). Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections. Emerg. Infect. Dis, 28 (5). S. 1050 - 1053. ATLANTA: CENTERS DISEASE CONTROL & PREVENTION. ISSN 1080-6059

Vanshylla, Kanika ORCID: 0000-0003-4552-9170, Tober-Lau, Pinkus ORCID: 0000-0002-9148-3663, Gruell, Henning, Muenn, Friederike, Eggeling, Ralf, Pfeifer, Nico ORCID: 0000-0002-4647-8566, Le, N. Han, Landgraf, Irmgard, Kurth, Florian ORCID: 0000-0002-3807-473X, Sander, Leif E. and Klein, Florian ORCID: 0000-0003-1376-1792 (2022). Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults. Lancet Infect. Dis., 22 (4). S. 445 - 447. OXFORD: ELSEVIER SCI LTD. ISSN 1474-4457

Habermann, Elisa ORCID: 0000-0003-1504-4746, Gieselmann, Lutz ORCID: 0000-0003-3699-3318, Tober-Lau, Pinkus ORCID: 0000-0002-9148-3663, Klotsche, Jens, Albach, Fredrik Nils, Ten Hagen, Alexander, Zernicke, Jan, Ahmadov, Elvin, de Silva, Amanthi Nadira Arumahandi, Frommert, Leonie Maria ORCID: 0000-0003-0110-9190, Kurth, Florian ORCID: 0000-0002-3807-473X, Sander, Leif Erik, Burmester, Gerd R., Klein, Florian ORCID: 0000-0003-1376-1792 and Biesen, Robert ORCID: 0000-0002-0434-7832 (2022). Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination. RMD Open, 8 (2). LONDON: BMJ PUBLISHING GROUP. ISSN 2056-5933

Gruell, Henning, Vanshylla, Kanika ORCID: 0000-0003-4552-9170, Tober-Lau, Pinkus ORCID: 0000-0002-9148-3663, Hillus, David, Schommers, Philipp, Lehmann, Clara, Kurth, Florian ORCID: 0000-0002-3807-473X, Sander, Leif E. and Klein, Florian ORCID: 0000-0003-1376-1792 (2022). mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant. Nat. Med., 28 (3). S. 477 - 483. BERLIN: NATURE PORTFOLIO. ISSN 1546-170X